FDA Issues Warning Letter to Amgen Over Misleading Vectibix Advertisement
The U.S. Food and Drug Administration (FDA) has issued a formal warning letter to Amgen regarding a television advertisement for its colorectal cancer medication, Vectibix (panitumumab). The regulatory agency determined that the promotional material creates a misleading impression concerning both the safety profile and the overall effectiveness of the treatment. This regulatory action highlights the FDA's ongoing oversight of pharmaceutical marketing practices. While the warning letter addresses specific communication failures in advertising, it serves as a reminder to biotech companies regarding the strict requirements for balancing efficacy claims with necessary risk disclosures in direct-to-consumer media.
Tickers: $AMGN